Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 8/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596149 | 0.87 | NOTUM (0.35) | DRD2CDK9NOTUMTRPM5SCN9A | |
| SCHEMBL5596620 | 0.87 | DRD2 (0.39) | DRD2CDK9NOTUMTRPM5 | |
| SCHEMBL5596683 | 0.82 | C5AR1 (0.35) | CDK9NOTUMHRH3 | |
| SCHEMBL5596820 | 0.81 | OPRM1 (0.34) | DRD2CDK9 | |
| SCHEMBL5597050 | 0.80 | DRD2 (0.35) | DRD2CDK9MERTKAXLTYRO3 | |
| SCHEMBL5596733 | 0.78 | NOTUM (0.35) | DRD2NOTUMMERTKAXLTYRO3 | |
| SCHEMBL5596769 | 0.78 | MEN1 (0.43) | MERTKAXLTYRO3KCNH2 | |
| SCHEMBL5596752 | 0.76 | PTPN11 (0.34) | DRD2 | |
| SCHEMBL5596996 | 0.73 | HTR6 (0.36) | DRD2CDK9NOTUM | |
| SCHEMBL5415547 | 0.69 | HTR2C (0.44) | DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | DRD2 1473/4885CDK9 1239/4885NOTUM 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.